A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis) (NCT04817007)

🧪 Interventions in This Study

• BMS-986158 (DRUG)
• Ruxolitinib (DRUG)
• Fedratinib (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (49 Sites)

Showing the first 25 of 49 sites.

• Local Institution - 0069 — Newport Beach, California
• Local Institution - 0090 — Lake Mary, Florida
• Local Institution - 0043 — New Orleans, Louisiana
• Local Institution - 0038 — Worcester, Massachusetts
• Local Institution - 0033 — Ann Arbor, Michigan
• Local Institution - 0045 — Hackensack, New Jersey
• Local Institution - 0076 — Chapel Hill, North Carolina
• Local Institution - 0042 — Pittsburgh, Pennsylvania
• Local Institution - 0036 — Blacktown, New South Wales
• Local Institution - 0032 — Wollongong, New South Wales
• Local Institution - 0007 — East Melbourne, Victoria
• Local Institution - 0006 — Heidelberg, Victoria
• Local Institution - 0041 — Nedlands, Western Australia
• Local Institution - 0015 — West Perth, Western Australia
• Local Institution - 0030 — Brest,
• Local Institution - 0008 — Marseille,
• Local Institution - 0027 — Nice,
• Local Institution - 0011 — Paris,
• Local Institution - 0010 — Villejuif,
• Local Institution - 0068 — Erding, Bavaria
• Local Institution - 0039 — Essen, North Rhine-Westphalia
• Local Institution - 0040 — Chemnitz, Saxony
• Local Institution - 0035 — Halle, Saxony-Anhalt
• Local Institution - 0050 — Lübeck, Schleswig-Holstein
• Local Institution - 0061 — Chaïdári, Attikí

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Myelofibrosis

• Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms — Birmingham, Alabama
• Study of Stem Cell Transplant vs. Non-Transplant Therapies in High-Risk Myelofibrosis — Calgary, Alberta
• Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis — Birmingham, Alabama
• Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2) — Birmingham, Alabama
• A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis — Pasadena, California

Explore by condition: All Myelofibrosis clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.